威海市免加盟费美甲店品牌电话多少钱(昆明市iu美甲加盟电话多少钱) (今日更新中)

SAN FRANCISCO, March 21 (Xinhua) -- Microsoft on Monday sued Barnes & Noble, claiming patent infringement by the largest book retailer in the United States.Microsoft said it filed legal actions on Monday in both the U.S. International Trade Commission and the U.S. District Court of the Western District of Washington against Barnes & Noble, as well as Foxconn and Inventec, two manufacturers of Barnes & Noble's devices.According to Microsoft, the actions focus on the patent infringement by Barnes & Noble's Nook e-reader and tablet, both of which run Google's Android operating system.The patents at issue cover a range of functionality embodied in Android devices that are essential to the user experience, including natural ways of interacting with devices by tabbing through various screens to find the information they need, surfing the Web more quickly and interacting with documents and e-books, Microsoft said in a press release."The Android platform infringes a number of Microsoft's patents, and companies manufacturing and shipping Android devices must respect our intellectual property rights," Horacio Gutierrez, Microsoft's corporate vice president and deputy general counsel, was quoted by the press release as saying.Writing in a separate company blog post, Gutierrez said that the latest actions bring to 25 the total number of Microsoft patents in litigation for infringement by Android smartphones, tablets and other devices.He noted that Microsoft has established a licensing program to address Android's ongoing infringement, and leading Android smartphone manufacturer HTC has taken a license under this program.Amazon.com also signed a patent license with Microsoft last year covering its Kindle e-reader, he added."Unfortunately, after more than a year of discussions, Barnes & Noble, Foxconn and Inventec have so far been unwilling to sign a license, and therefore, we have no other choice but to bring legal action to defend our innovations," Gutierrez said in the blog post.

BEIJING, May 21 (Xinhua) -- China's State Food and Drug Administration (SFDA) issued a circular on Friday banning the use of Nimesulide, an anti-inflammatory drug, for children under the age of 12, considering potential side-effects such as liver and kidney damage.Nimesulide is a non-steroidal anti-inflammatory drug that first became available in Italy in 1985. It is now used in more than 50 countries and regions.The drug entered Chinese markets in 1997.According to the SFDA, while common adverse reactions to the drug include vomiting and stomache, domestic and overseas statistics indicate that more severe issues are related to the drug, such as blood coagulation disorders, decreased white blood cells and damage to liver and kidney.Previously, the SFDA only prevented the use of the drug among children one year old or younger.Also on Friday, the SFDA ordered the suspension of the production, sales and use of Duxil (almitrine and raubasine compound) due to its "unobvious" efficacy.According to the SFDA, clinical research found "little" evidence proving the drug effectively improves the cognitive ability for patients suffering vascular cognitive impairment.The drug was supposed to treat symptoms related to cognition and sensory nerve damage.The moves came after a two-month nationwide campaign was launched earlier this month to probe the quality of essential drugs and ensure drug safety.Official figures show that China's National Center for Adverse Drug Reaction Monitoring received 692,904 reports of adverse reactions in 2010, up 8.4 percent compared with those in 2009.Among the total, 109,991 cases involved new or severe adverse reactions, a year-on-year increase of 16.2 percent.

WASHINGTON, May 27 (Xinhua) -- Two U.S. astronauts conducted the fourth and final scheduled spacewalks for space shuttle Endeavour 's STS-134 mission on Friday morning, the U.S. National Aeronautics and Space Administration (NASA) announced.The seven-hour, 24-minute spacewalk completed by Mike Fincke and Greg Chamitoff at 7:39 a.m. EDT (1139 GMT) was the final spacewalk conducted by space shuttle astronauts before NASA turns over Endeavour and sister ships Discovery and Atlantis to museums. Space station crew will continue to make spacewalks for maintenance and repair tasks.At 5:02 a.m. (0902 GMT), Fincke and Chamitoff surpassed the 1, 000th hour astronauts and cosmonauts have spent spacewalking in support of space station assembly and maintenance. The milestone occurred four hours and 47 minutes into the spacewalk, the 159th in support of station assembly and maintenance, totaling 1,002 hours, 37 minutes.The astronauts completed their mission to stow the 50-foot-long boom on the station truss and work on some new installations to extend the space station's robotic arm. After that, shuttle commander Mark Kelly called Mission Control in Houston to mark the milestone -- after 12 years of efforts."Space station assembly is complete," Kelly said.It was the 248th spacewalk U.S. astronauts have conducted and the 118th from space station airlocks. Landing is scheduled for 2: 32 a.m. EDT (0632 GMT) on Wednesday at the Kennedy Space Center in Florida. Shuttle Atlantis is targeted to launch on July 8 for space shuttle's final flight.Endeavour lifted off on May 16 from the Kennedy Space Center in Florida, to deliver to the International Space Station a 2-billion- dollar, multinational particle detector known as the Alpha Magnetic Spectrometer (AMS).AMS, a particle physics detector, is designed to search for various types of unusual matter by measuring cosmic rays. Its experiments are designed to help researchers study the formation of the universe and search for evidence of dark matter, strange matter and antimatter.NASA's 30-year-old shuttle program is ending due to high operating costs. The Obama administration wants to spur private companies to get into the space taxi business, freeing NASA to focus on deep space exploration and new technology development.When the U.S. space shuttle program officially ends later this year, the Russian space program's Soyuz capsule will be the only method for transporting astronauts to and from the station.

ABU DHABI, Feb. 10 (Xinhua) -- China believes that Egypt has sufficient wisdom and capability to overcome difficulties and realize national stability and development, visiting Chinese Foreign Minister Yang Jiechi told his Egyptian counterpart in a telephone conversation Thursday.Yang, who was on a visit to the United Arab Emirates (UAE), told the Egyptian Foreign Minister Ahmed Abul Gheit that China pays close attention to the situation in Egypt, adding that Egypt, as an influential country in the Middle East, is vital to the region's stability.Egypt's internal affairs should be resolved by Egyptians themselves and should be free of outside interference, he added.Gheit briefed Yang on Egypt's situation, saying his government was taking measures to safeguard social stability and return the country to normality.Both sides also expressed satisfaction with the development of China-Egypt relations in the past year, saying the strategic cooperation between the two countries has great potential and broad development prospects.Yang arrived in the UAE capital of Abu Dhabi late Wednesday for an official visit to the Gulf nation.

WASHINGTON, April 25 (Xinhua) -- A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.Working in cell lines from colorectal cancer patients, researchers found that the class of drugs called PARP inhibitors worked against tumors with mutations in the MRE11 gene.About 15 percent of all colorectal cancers have what's called microsatellite instability, a type of error in the DNA. About 82 percent of those tumors have the MRE11 gene mutation."This is a potential broader application for PARP inhibitors, beyond breast and ovarian cancer. This is a class of drug that's already shown safety in early clinical trials and now might benefit some colorectal cancer patients as well," says lead study author Eduardo Vilar-Sanchez, a hematology/oncology fellow at the university, in a statement.The study, which was published Monday in Cancer Research, also found that PARP inhibitors are even more effective when both copies of MRE11 were mutated. Each person carries two copies of each gene, which means mutations can occur in either one or both copies. The researchers suggest that PARP inhibitors could be targeted specifically to colorectal cancer patients who have two copies of the mutated gene.Researchers are planning a phase I clinical trial to look at using PARP inhibitors in colorectal cancer patients with two mutated copies of MRE11. Future trials are being considered using PARP inhibitors to prevent colorectal cancer and other cancers in people with Lynch syndrome whose tumors have this mutation.Microsatellite instability is also seen in prostate cancer and endometrial cancer, suggesting potential for PARP inhibitors to play a role in additional types of cancer as well, Vilar-Sanchez says, adding that more research is needed in these areas.

来源：资阳报